

Rabbit Neu Polyclonal Antibody

Neu (C18) Antibody

CATALOG #	HOST	REACTIVITY	APPLICATIONS
AAA63011	Rabbit	Mouse, rat, human	Immunohistochemistry, Immunoprecipitation, Western Blot


PRODUCT SYNONYMS

Neu; Polyclonal Antibody; Neu (C18) Antibody; anti-Neu antibody

PRODUCT SPECIFICATIONS

Host	Rabbit
Reactivity	Mouse, rat, human
Clonality	Polyclonal
Specificity	Mouse, rat, and human Neu
Form/Format	Each vial contain 200ug/ml of affinity purified rabbit IgG Neu (C18), in 1ml PBS containing 0.1% sodium azide and 0.2% gelatin.
Concentration	0.200 mg/ml (varies by lot)
Applicable Applications for anti-Neu antibody	IHC (Immunohistochemistry), IP (Immunoprecipitation), WB (Western Blot)
Origin	Neu (C18) is provided as an affinity purified rabbit polyclonal antibody, raised against a peptide mapping to the carboxy terminus of human Neu (HER2 or ErbB-2).
Immunogen	Synthetic peptide mapping to the carboxy terminus of human Neu (HER2 or ErbB-2).
Competition studies	A blocking peptide is also available for use in competition studies. Each vial contains 100ug of peptide in 0.5ml PBS with 0.1% sodium azide and 100 ug BSA.
Preparation and Storage	Store this product at 4 degree C, do not freeze. The product is stable for one year from the date of shipment.

IMAGES



WB (Western Blot)

ADDITIONAL INFORMATION

Related Product Information for anti-Neu antibody

The Neu/HER-2 (also known as EGFR-2 or ErbB-2) is a transmembrane tyrosine kinase receptor and a well-defined tumor antigen. Neu/HER-2 is a shared antigen among multiple tumor types. Patients with HER-2/neu protein-overexpressing breast, ovarian, non-small cell lung, colon, and prostate cancers have been shown to have a pre-existent immune response to Neu/HER-2 (1,2). Neu/HER-2 amplification/overexpression confers more aggressive and malignant characteristics on breast cancer cells. Patients with Neu/HER-2-amplified breast cancer have a worse prognosis than those with normal Neu/HER-2 expression (3).

References

1. Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML. Vaccination against the HER-2/neu oncogenic protein. Int J Endocr Relat Cancer 2002 Mar;9(1):33-44.
2. Lohrisch C, Piccart M. HER2/neu as a predictive factor in breast cancer. Clin Breast Cancer 2001 Jul;2(2):129-35; discussion 136-7.
3. Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 2001 Dec;28(6 Suppl 18):43-7

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com

Online datasheet: <https://stage.aaabiotech.com/polyclonal/neu-antibody-immunohistochemistry-immunoprecipitation-western-blot-elisa/63011>